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CASE REPORTA case of leukocytoclastic vasculitis
following influenza vaccination
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LCV: leukocytoclastic vasculitisINTRODUCTION
Leukocytoclastic vasculitis (LCV) is a small-vessel
vasculitis that presents with palpable purpura, most
often on the lower extremities. The most common
identified triggers of LCVare infection or exposure to
a new medication. However, in many cases, a cause
cannot be identified.1 We present a patient who had
LCV during the fall season of 2 consecutive years. A
cause could not be identified at the time of the initial
presentation. However, upon recurrence 1 year later,
it was discovered that both episodes occurred
11 days after influenza vaccination.CASE REPORT
An 89-year-old woman with well-controlled
diabetes mellitus and hypertension presented with
a 3-day history of a pruritic eruption on the legs. On
examination, she had nonblanching erythematous-
to-violaceous macules that coalesced into patches, in
addition to palpable purpura, on the bilateral lower
extremities (Fig 1). She otherwise felt well and
denied fever, chills, dysuria, nausea, vomiting,
abdominal pain, or upper respiratory symptoms.
She denied taking new medications. Biopsy findings
from a purpuric papule on the thigh were consistent
with leukocytoclastic vasculitis (Fig 2). Complete
blood count showed mild anemia and thrombocy-
topenia. Urinalysis result was within normal limits.
Without an obvious infection or medication trigger,
the patient’s history of paraproteinemia was sus-
pected as a possible inciting factor. The hematology
department determined that there was a possibility
of lymphoma; however, the patient was otherwise
asymptomatic and elected to monitor rather thanthe Department of Dermatology, The University of Texas
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hilip@utmb.edu.intervene. Five days after initial presentation, the
eruption was markedly improved, with predomi-
nantly postinflammatory hyperpigmentation remain-
ing. Complete resolution occurred within 3 weeks.
One year later, the patient presented with a
recurrence of scattered erythematous nonblanching
macules and palpable purpura on the bilateral lower
extremities. Similar to the previous episode, review
of systems was otherwise negative. She denied
taking new medications or having recent infection.
Complete blood count showed mild pancytopenia.
Urinalysis result was within normal limits. During the
interim, the patient had undergone radiologic imag-
ing and had no evidence of a clinically significant
lymphoma. Chart review revealed that the patient
had received the influenza vaccine 11 days before
the onset of the current eruption. Upon further
investigation, it was discovered that the patient also
received the influenza vaccine 11 days before the
onset of the initial eruption 1 year before. The final
diagnosis is suspected to be LCV secondary to the
influenza vaccine, given the identical onset of the
episodes 11 days after vaccination and complete
resolution between the 2 exposures. The patient was
counseled to avoid the influenza vaccine next year.DISCUSSION
LCV is a small-vessel vasculitis that presents with
palpable purpura, most commonly observed on theJAAD Case Reports 2016;2:340-2.
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Fig 1. The patient presented with nonblanching erythem-
atous and violaceous macules coalescing into patches, in
addition to palpable purpura, on the bilateral lower
extremities.
Fig 2. Leukocytoclastic vasculitis. Postcapillary venules
and capillary loops in the papillary dermis show fibrinoid
necrosis, infiltration of vessel walls by neutrophils, and
surrounding conspicuous nuclear dust and extravasated
erythrocytes. (Hematoxylin-eosin stain.)
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terized by fibrinoid necrosis of the vessel wall with
frequent neutrophils, nuclear dust, and extravasated
erythrocytes.1 Although thorough evaluation to
determine the etiology is recommended, most cases
are idiopathic. The most common identified triggers
are acute infection or a new medication. Foods,
autoimmune disease, collagen vascular disease, and
malignancy are also associated with LCV.1,2
In this case, the patient received the influenza
vaccine 11 days before the onset of eruptions in
2 consecutive years. The patient had complete
resolution within 3 weeks of both episodes and
had no disease activity between episodes. The
patient had not started any other medications before
either incident. The patient had a history of
paraproteinemia, without evidence of clinically
significant lymphoma on recent imaging.
LCV caused by the influenza virus infection has
been reported in several previous cases.3-5 Lee et al5
reported on a 2-year-old girl who presented with
palpable purpuric lesionswith confirmed influenzaA
infection. In addition, there are some reported cases
of vasculitis following influenza vaccination. Similar
to our case, most of those patients were elderly with
onset of the eruption 7 to 14 days after administration
of the influenza vaccine. Some of these previously
reported cases showed renal involvement with
abnormal urinalysis.6-10 Fortunately, our patient
showed no sign of systemic involvement. LCV hasalso been reported following administration of the
pneumococcal, meningococcal, hepatitis A, and
hepatitis B vaccinations.11-14 Onset after these
vaccine administrations similarly ranged from 7 to
14 days. There were no common risk factors for LCV
identified in the previous cases aside from the
administration of a vaccine. There is a need for
further research to determine a causative link be-
tween LCV and vaccinations. Park et al15 proposed
that LCV after hepatitis A vaccination may be a result
of hepatitis A antigeneinduced production of
interleukin-10; however, no studies have been
conducted.15 The temporal nature of these cases
of vasculitis following vaccination suggests an
immunopathogenic link that has yet to be explained.
It is interesting to consider the role of para-
proteinemia in this case. Although the timing of the
patient’s episodes of LCV provides strong support for
the vaccine’s role, we must consider the possibility
that an underlying paraproteinemia may have made
the patient more susceptible to the eruption.
Previous cases attributed to a vaccine had no other
identified precipitating factors. However, we pro-
pose that it is prudent to perform a thorough search
for additional etiologic agents, such as paraprotei-
nemia, particularly in a patient with recurrent LCV.
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